{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:15:52Z","timestamp":1791400552044,"version":"4.3.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,7,3]],"date-time":"2008-07-03T00:00:00Z","timestamp":1215043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,7,3]],"date-time":"2008-07-03T00:00:00Z","timestamp":1215043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1038\/leu.2008.175","type":"journal-article","created":{"date-parts":[[2008,7,3]],"date-time":"2008-07-03T10:03:13Z","timestamp":1215079393000},"page":"1712-1720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells"],"prefix":"10.1038","volume":"22","author":[{"given":"P","family":"P\u00e9rez-Gal\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"L\u00f3pez-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Villamor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Montserrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G C","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,7,3]]},"reference":[{"key":"BFleu2008175_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMra041720","volume":"352","author":"N Chiorazzi","year":"2005","unstructured":"Chiorazzi N, Rai KR, Ferrarini M . Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804\u2013815.","journal-title":"N Engl J Med"},{"key":"BFleu2008175_CR2","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1056\/NEJMoa023143","volume":"348","author":"M Crespo","year":"2003","unstructured":"Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764\u20131775.","journal-title":"N Engl J Med"},{"key":"BFleu2008175_CR3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1172\/JCI23409","volume":"115","author":"BT Messmer","year":"2005","unstructured":"Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755\u2013764.","journal-title":"J Clin Invest"},{"key":"BFleu2008175_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2567.2005.02117.x","volume":"114","author":"G Packham","year":"2005","unstructured":"Packham G, Stevenson FK . Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 2005; 114: 441\u2013449.","journal-title":"Immunology"},{"key":"BFleu2008175_CR5","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","volume":"91","author":"S Kitada","year":"1998","unstructured":"Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379\u20133389.","journal-title":"Blood"},{"key":"BFleu2008175_CR6","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","volume":"26","author":"JM Adams","year":"2007","unstructured":"Adams JM, Cory S . The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324\u20131337.","journal-title":"Oncogene"},{"key":"BFleu2008175_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","volume":"2","author":"A Letai","year":"2002","unstructured":"Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ . Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183\u2013192.","journal-title":"Cancer Cell"},{"key":"BFleu2008175_CR8","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1101\/gad.1304105","volume":"19","author":"SN Willis","year":"2005","unstructured":"Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294\u20131305.","journal-title":"Genes Dev"},{"key":"BFleu2008175_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.cdd.4400998","volume":"9","author":"H Puthalakath","year":"2002","unstructured":"Puthalakath H, Strasser A . Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002; 9: 505\u2013512.","journal-title":"Cell Death Differ"},{"key":"BFleu2008175_CR10","doi-asserted-by":"crossref","first-page":"26865","DOI":"10.1016\/S0021-9258(18)47099-8","volume":"269","author":"WS May","year":"1994","unstructured":"May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE . Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem 1994; 269: 26865\u201326870.","journal-title":"J Biol Chem"},{"key":"BFleu2008175_CR11","first-page":"659","volume":"13","author":"A Basu","year":"1998","unstructured":"Basu A, Haldar S . Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int J Oncol 1998; 13: 659\u2013664.","journal-title":"Int J Oncol"},{"key":"BFleu2008175_CR12","doi-asserted-by":"publisher","first-page":"11671","DOI":"10.1074\/jbc.272.18.11671","volume":"272","author":"T Ito","year":"1997","unstructured":"Ito T, Deng X, Carr B, May WS . Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997; 272: 11671\u201311673.","journal-title":"J Biol Chem"},{"key":"BFleu2008175_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/sj.leu.2402090","volume":"15","author":"PP Ruvolo","year":"2001","unstructured":"Ruvolo PP, Deng X, May WS . Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001; 15: 515\u2013522.","journal-title":"Leukemia"},{"key":"BFleu2008175_CR14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/sj.leu.2404248","volume":"20","author":"S Kurinna","year":"2006","unstructured":"Kurinna S, Konopleva M, Palla SL, Chen W, Kornblau S, Contractor R et al. Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML. Leukemia 2006; 20: 1316\u20131319.","journal-title":"Leukemia"},{"key":"BFleu2008175_CR15","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/sj.emboj.7600104","volume":"23","author":"MC Bassik","year":"2004","unstructured":"Bassik MC, Scorrano L, Oakes SA, Pozzan T, Korsmeyer SJ . Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. EMBO J 2004; 23: 1207\u20131216.","journal-title":"EMBO J"},{"key":"BFleu2008175_CR16","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1128\/MCB.20.5.1886-1896.2000","volume":"20","author":"K Breitschopf","year":"2000","unstructured":"Breitschopf K, Haendeler J, Malchow P, Zeiher AM, Dimmeler S . Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol Cell Biol 2000; 20: 1886\u20131896.","journal-title":"Mol Cell Biol"},{"key":"BFleu2008175_CR17","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1084\/jem.189.11.1815","volume":"189","author":"S Dimmeler","year":"1999","unstructured":"Dimmeler S, Breitschopf K, Haendeler J, Zeiher AM . Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J Exp Med 1999; 189: 1815\u20131822.","journal-title":"J Exp Med"},{"key":"BFleu2008175_CR18","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.exphem.2006.07.008","volume":"34","author":"C Campas","year":"2006","unstructured":"Campas C, Cosialls AM, Barragan M, Iglesias-Serret D, Santidrian AF, Coll-Mulet L et al. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp Hematol 2006; 34: 1663\u20131669.","journal-title":"Exp Hematol"},{"key":"BFleu2008175_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1172\/JCI28281","volume":"117","author":"V Del Gaizo Moore","year":"2007","unstructured":"Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A . Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112\u2013121.","journal-title":"J Clin Invest"},{"key":"BFleu2008175_CR20","doi-asserted-by":"publisher","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","volume":"23","author":"SM O'Brien","year":"2005","unstructured":"O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR . Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 7697\u20137702.","journal-title":"J Clin Oncol"},{"key":"BFleu2008175_CR21","doi-asserted-by":"publisher","first-page":"19512","DOI":"10.1073\/pnas.0709443104","volume":"104","author":"M Nguyen","year":"2007","unstructured":"Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104: 19512\u201319517.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2008175_CR22","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","volume":"109","author":"P Perez-Galan","year":"2007","unstructured":"Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D . The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007; 109: 4441\u20134449.","journal-title":"Blood"},{"key":"BFleu2008175_CR23","first-page":"2654","volume":"108","author":"G Borthakur","year":"2006","unstructured":"Borthakur G, O'Brien S, Ravandi-Kashani F, Giles F, Schimmer AD, Viallet J et al. A phase I trial of the small molecule pan-bcl-2 family inhibitor obatoclax mesylate (GX15-070) administered by 24\u2009h infusion every 2 weeks to patients with myeloid malignancies and chronic lymphocytic leukemia (CLL). ASH Annu Meet Abstr 2006; 108: 2654.","journal-title":"ASH Annu Meet Abstr"},{"key":"BFleu2008175_CR24","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/sj.emboj.7600592","volume":"24","author":"M Germain","year":"2005","unstructured":"Germain M, Mathai JP, McBride HM, Shore GC . Endoplasmic reticulum BIK initiates DRP1-regulated remodelling of mitochondrial cristae during apoptosis. EMBO J 2005; 24: 1546\u20131556.","journal-title":"EMBO J"},{"key":"BFleu2008175_CR25","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.4049\/jimmunol.178.3.1923","volume":"178","author":"G Roue","year":"2007","unstructured":"Roue G, Perez-Galan P, Lopez-Guerra M, Villamor N, Campo E, Colomer D . Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 2007; 178: 1923\u20131930.","journal-title":"J Immunol"},{"key":"BFleu2008175_CR26","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","volume":"68","author":"M Konopleva","year":"2008","unstructured":"Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008; 68: 3413\u20133420.","journal-title":"Cancer Res"},{"key":"BFleu2008175_CR27","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1182\/blood-2006-10-047951","volume":"109","author":"S Trudel","year":"2007","unstructured":"Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK . Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007; 109: 5430\u20135438.","journal-title":"Blood"},{"key":"BFleu2008175_CR28","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1073\/pnas.97.4.1578","volume":"97","author":"X Deng","year":"2000","unstructured":"Deng X, Ruvolo P, Carr B, May Jr WS . Survival function of ERK1\/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 2000; 97: 1578\u20131583.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2008175_CR29","doi-asserted-by":"publisher","first-page":"23003","DOI":"10.1074\/jbc.M602648200","volume":"281","author":"SS Lin","year":"2006","unstructured":"Lin SS, Bassik MC, Suh H, Nishino M, Arroyo JD, Hahn WC et al. PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem 2006; 281: 23003\u201323012.","journal-title":"J Biol Chem"},{"key":"BFleu2008175_CR30","doi-asserted-by":"publisher","first-page":"13856","DOI":"10.1074\/jbc.272.21.13856","volume":"272","author":"B Favre","year":"1997","unstructured":"Favre B, Turowski P, Hemmings BA . Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid, and tautomycin. J Biol Chem 1997; 272: 13856\u201313863.","journal-title":"J Biol Chem"},{"key":"BFleu2008175_CR31","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/cncr.22097","volume":"107","author":"S Faderl","year":"2006","unstructured":"Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O\u2032Brien S et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 2006; 107: 916\u2013924.","journal-title":"Cancer"},{"key":"BFleu2008175_CR32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.leu.2402528","volume":"16","author":"MJ Dyer","year":"2002","unstructured":"Dyer MJ, Oscier DG . The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia. Leukemia 2002; 16: 973\u2013984.","journal-title":"Leukemia"},{"key":"BFleu2008175_CR33","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.0506654102","volume":"102","author":"A Cimmino","year":"2005","unstructured":"Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944\u201313949.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2008175_CR34","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1182\/blood-2006-12-062398","volume":"109","author":"V Fulci","year":"2007","unstructured":"Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109: 4944\u20134951.","journal-title":"Blood"},{"key":"BFleu2008175_CR35","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.leu.2403398","volume":"18","author":"S Cuni","year":"2004","unstructured":"Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM et al. A sustained activation of PI3K\/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004; 18: 1391\u20131400.","journal-title":"Leukemia"},{"key":"BFleu2008175_CR36","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1182\/blood-2004-03-0889","volume":"106","author":"M Nishio","year":"2005","unstructured":"Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005; 106: 1012\u20131020.","journal-title":"Blood"},{"key":"BFleu2008175_CR37","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1182\/blood-2004-07-2669","volume":"105","author":"A Petlickovski","year":"2005","unstructured":"Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005; 105: 4820\u20134827.","journal-title":"Blood"},{"key":"BFleu2008175_CR38","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/sj.cdd.4401937","volume":"13","author":"D Zhai","year":"2006","unstructured":"Zhai D, Jin C, Satterthwait AC, Reed JC . Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006; 13: 1419\u20131421.","journal-title":"Cell Death Differ"},{"key":"BFleu2008175_CR39","first-page":"446","volume":"106","author":"S O'Brien","year":"2005","unstructured":"O'Brien S, Kipps TJ, Faderl S, Crump M, Keating MJ, Anderson B et al. A phase I trial of the small molecule Pan-Bcl-2 family inhibitor GX15-070 administered intravenously (IV) every 3 weeks to patients with previously treated chronic lymphocytic leukemia (CLL). ASH Annu Meet Abstr 2005; 106: 446.","journal-title":"ASH Annu Meet Abstr"},{"key":"BFleu2008175_CR40","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1182\/blood-2005-04-1718","volume":"107","author":"SJ Richardson","year":"2006","unstructured":"Richardson SJ, Matthews C, Catherwood MA, Alexander HD, Carey BS, Farrugia J et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107: 3584\u20133592.","journal-title":"Blood"},{"key":"BFleu2008175_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375\u2013388.","journal-title":"Cancer Cell"},{"key":"BFleu2008175_CR42","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","volume":"27","author":"DA Fennell","year":"2008","unstructured":"Fennell DA, Chacko A, Mutti L . BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 2008; 27: 1189\u20131197.","journal-title":"Oncogene"},{"key":"BFleu2008175_CR43","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P Perez-Galan","year":"2006","unstructured":"Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D . The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257\u2013264.","journal-title":"Blood"},{"key":"BFleu2008175_CR44","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1158\/0008-5472.CAN-05-2321","volume":"66","author":"M Bazzaro","year":"2006","unstructured":"Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih I et al. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006; 66: 3754\u20133763.","journal-title":"Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2008175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2008175","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2008175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:06:31Z","timestamp":1648724791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2008175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,3]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["BFleu2008175"],"URL":"https:\/\/doi.org\/10.1038\/leu.2008.175","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,3]]},"assertion":[{"value":"21 November 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}